Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438)

Clinical Cancer Research

Volumn 18, Issue 4, 2012, Pages 1129-1137

  Margolin, Kim A ^a   Moon, James ^b   Flaherty, Lawrence E ^c   Lao, Christopher D ^d   Akerley III, Wallace L ^e   Othus, Megan ^b   Sosman, Jeffrey A ^f   Kirkwood, John M ^g   Sondak, Vernon K ^h  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SWOG STATISTICAL CENTER   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f VANDERBILT UNIVERSITY   (United States)

^g UNIVERSITY OF PITTSBURGH   (United States)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FARNESYL TRANS TRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN; SORAFENIB; TEMSIROLIMUS; TIPIFARNIB;

ACNE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ERYTHEMA MULTIFORME; ERYTHROCYTE DISORDER; EVENING DOSAGE; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPOPHOSPHATEMIA; KIDNEY FAILURE; LEUKOCYTE DISORDER; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MOLECULARLY TARGETED THERAPY; MORNING DOSAGE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NEUTROPHILIA; OVERALL SURVIVAL; PANCREATITIS; PHARMACOLOGICAL BLOCKING; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMACH HEMORRHAGE; THROMBOCYTE DISORDER; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; WEAKNESS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PYRIDINES; QUINOLONES; SIROLIMUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84857073184     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2488     Document Type: Article

References (26)

1. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47. (Pubitemid 41653105)
2. Nazarian R, Shi H, Wang Q, Kog X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973-7.
3. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010;18:683-95.
4. Patnaik A, Ricart A, Cooper J, Papadopoulos K, Beeram M, Mita C, et al. A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies. J Clin Oncol 25:18Sm 2007 (suppl; abstr 3512).
5. Kim KB, Davies MA, Papadopoulos NE, Bedikian AY, Hwu W, Woodard K, et al. Phase I/II study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. J Clin Oncol 27:15s, 2009 (suppl; abstr 9026).
6. Hong DS, Sebti S, Newman R, Blaskovich MA, Ye L, Gagel RF, et al. Phase I trial of a combination of the multikinase inhibitor Sorafenib and the farnesyltransferase inhibitor Tipifarnib in advanced malignancies. Clin Cancer Res 2009;15:7061-8.
7. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417: 949-54. (Pubitemid 34716871)
8. Madhunapantula SV, Robertson GP. The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res 2009;22:400-19.
9. Gorden A, Osman I, Gai W, He D, Huang W, Davidson A, et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 2003;63:3955-7. (Pubitemid 36917911)
10. Molhoek KR, Brautigan DL, Slingluff CL Jr. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J Transl Med 2005;3:39.
11. Meier F, Busch S, Lasithiotakis K, Kulms D, Garbe C, Maczey E, et al. Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br J Dermatol 2007;156: 1204-13. (Pubitemid 47029801)
12. Molhoek KR, Griesemann H, Shu J, Gershenwald JE, Brautigan DL, Slingluff CL Jr. Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. Cancer Res 2008;68:4392-7.
13. Green SJ, Dahlberg S. Planned versus attained design in phase II clinical trials. Stat Med 1992;11:853-62.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
15. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982;38:29-41.
16. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 2006;95:581-6. (Pubitemid 44325897)
17. Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, Redlinger M, et al. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 2008;14; 4836-42.
18. Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J, et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 2005;104:1045-8. (Pubitemid 41170233)
19. Gajewski TF, Niedzwiecki D, Johnson J, Linette G, Bucher C, Blaskovich M, et al. Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma: CALGB 500104. J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006:8014.
20. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008;26:527-34. (Pubitemid 351264344)
21. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
22. Arkenau HT, Kefford R, Long GV. Targeting BRAF for patients with melanoma. Br J Cancer 2011;104:392-8.
23. Kefford R, Arkenau H, Brown MP, Millward M, Infante JR, Long GV, et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 28:15s, 2010 (suppl; abstr 8503).
24. Downward J. Targeting RAF: trials and tribulations. Nat Med 2011; 17:286-8.
25. van der Heijden MS, Bernards R. Inhibition of the PI3K pathway: hope we can believe in? Clin Cancer Res 2010;16:3094-9.
26. Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007;13:3109-14. (Pubitemid 46944891)